Theravance Biopharma, Inc. faced a downgrade in revenue and earnings forecasts by analysts, impacting shareholder sentiment. Despite a cut in estimates, the company is expected to see revenue growth surpassing industry peers. The focus remains on long-term earnings trajectory and insider ownership.